Gene expression analysis in lymphoblasts derived from patients with autism spectrum disorder

Yuka Yasuda1,2, Ryota Hashimoto1,2,3*, Hidenaga Yamamori1,4, Kazutaka Oh1,2, Motoyuki Fukumoto1,2, Satomi Umeda-Yano4, Ikuko Mohri3,5, Akira Ito6, Masako Taniike3,5 and Masatoshi Takeda1,3

Abstract

Background: The autism spectrum disorders (ASDs) are complex neurodevelopmental disorders that result in severe and pervasive impairment in the development of reciprocal social interaction and verbal and nonverbal communication skills. In addition, individuals with ASD have stereotypical behavior, interests and activities. Rare mutations of some genes, such as neuroligin (NLGN 3/4), neurexin (NRXN)1, SHANK3, MeCP2 and NHE9, have been reported to be associated with ASD. In the present study, we investigated whether alterations in mRNA expression levels of these genes could be found in lymphoblastoid cell lines derived from patients with ASD.

Methods: We measured mRNA expression levels of NLGN3/4, NRXN1, SHANK3, MeCP2, NHE9 and AKT1 in lymphoblastoid cells from 35 patients with ASD and 35 healthy controls, as well as from 45 patients with schizophrenia and 45 healthy controls, using real-time quantitative reverse transcriptase polymerase chain reaction assays.

Results: The mRNA expression levels of NLGN3 and SHANK3 normalized by β-actin or TBP were significantly decreased in the individuals with ASD compared to controls, whereas no difference was found in the mRNA expression level of MeCP2, NHE9 or AKT1. However, normalized NLGN3 and SHANK3 gene expression levels were not altered in patients with schizophrenia, and expression levels of NLGN4 and NRXN1 mRNA were not quantitatively measurable in lymphoblastoid cells.

Conclusions: Our results provide evidence that the NLGN3 and SHANK3 genes may be differentially expressed in lymphoblastoid cell lines from individuals with ASD compared to those from controls. These findings suggest the possibility that decreased mRNA expression levels of these genes might be involved in the pathophysiology of ASD in a substantial population of ASD patients.

Background

Autism spectrum disorder (ASD), also known as pervasive developmental disorder (PDD), is defined as severe and pervasive impairments in the development of reciprocal social interaction and verbal and nonverbal communication skills. These disorders are also characterized by stereotypical behavior, interests and activities. The lifetime morbidity rate of ASD is 0.2% to 1.0% across studies [1]. In addition, twin and family studies of ASD have demonstrated a high heritability of approximately 90% [2], indicating that ASD is a heterogeneous condition that is likely to result from the combined effects of multiple genetic factors interacting with environmental factors. Recent genetic studies have identified several vulnerability loci and genetic mutations that cause ASD. One of the most striking revelations is the important role of genes that encode proteins at the neuronal synapse [3].

Rare mutations in the neuroligin 3 (NLGN3) and neuroligin 4 (NLGN4) genes, which map to chromosomes Xq13 and Xp22.3, have been reported in some patients with ASD and other neurodevelopmental impairments [4-8]. A particular mutation of NLGN3 (Arg451Cys) is known to cause a defect in protein processing of NLGN3 [9]. In addition, a particular mutation of NLGN4 (1186insT) causes a frameshift mutation that leads to premature termination of NLGN4 (D396X), resulting in a loss of 421 amino acids (51% of the
protein) [4]. Neuroligins, which are postsynaptically localized cell adhesion molecules, play a crucial role in organizing excitatory glutamatergic and inhibitory GABAergic synapses in the mammalian brain by interacting with presynaptic β-neurexins (NRXN), thereby triggering the formation of functional presynaptic structures in contacting axons [10]. Mutations of the neurexin 1 (NRXN1) gene, at the chromosome locus 2q32, have been found in individuals with ASD [11-14]. Furthermore, de novo copy number variation analysis revealed deletion of the NRXN1-containing gene region in ASD [15]. The binding of NRXN1 and NLGN genes mediates synaptic development [16]. Interestingly, a mutation of NLGN3 results in a disruption of the ability to bind to NRXN [9]. In addition, neuroligins interact with a postsynaptic scaffolding protein, SHANK3, which is also implicated in ASD [17] and is located on the telomeric terminal of chromosome 22q13.3. Shank proteins couple neurotransmitter receptors, ion channels and other membrane proteins to the actin cytoskeleton and G protein-coupled signaling pathways, and they also play a role in synapse formation and dendritic spine maturation [18]. Deletion or translocation of the genomic locus, which includes the SHANK3 gene, and de novo mutations of the SHANK3 gene result in premature stop codons and have been found in ASD [17,19,20].

In a study of consanguineous autism families, Morrow et al. [21] observed a relationship between ASD and alterations in the sodium/hydrogen exchanger 9 (NHE9) gene. Specifically, they found a nonsense mutation in patients with ASD that is a heterozygous CGA-to-TGA transition, changing arginine 423 to a stop codon [21]. The NHE9 gene is located on chromosome 3q24 and is one of the families of Na+/H+ exchangers that regulate ion flux across membranes [22]. Rett syndrome is another PDD, and the methyl-CpG-binding protein 2 (MECP2) gene is a causal gene for Rett syndrome. MECP2 is a transcriptional repressor that binds to methylated CpG dinucleotides generally located at gene promoters and recruits histone deacetylase 1 and other proteins involved in chromatin repression [23]. De novo mutations of the MECP2 gene located on chromosome Xp28 occur in 80% of female patients with Rett syndrome [24]. Some evidence of dysregulation of the phosphatidylinositol 3-kinase (PI3K)/AKT pathway is implicated in ASD, despite the fact that no mutation which causes ASD has been reported in association with the AKT1 gene. The expression and phosphorylation and/or activation of AKT were found to be decreased in the autistic brain [25]. The PTEN gene (phosphatase and tensin homolog deleted on chromosome 10) is a major negative regulator of the PI3K/AKT pathway, and PTEN mutations have been linked to ASD [26].

Recently, several studies have suggested that lymphoblastoid cells can be used to detect biologically plausible correlations between candidate genes and neuropsychiatric diseases, including Rett syndrome [27], nonspecific X-linked mental retardation [28], bipolar disorder [29], fragile X syndrome [30,31] and dup(15q) [32]. In the present study, we compared mRNA expression levels of various genes in blood-derived lymphoblastoid cells from individuals with ASD and healthy controls.

**Methods**

**Participants**

We obtained mRNA samples from patients with ASD, patients with schizophrenia and healthy controls from the research bioresource of the Human Brain Phenotype Consortium in Japan (http://www.sp-web.sakura.ne.jp/consortium.html). The ASD cohort consisted of 35 patients with ASD and healthy controls (Table 1). Patients with ASD and patients with schizophrenia were recruited from both outpatient and inpatient services at Osaka University Hospital. Each ASD patient was diagnosed by at least two trained child psychiatrists and/or child neurologists according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition—Text Revision (DSM-IV-TR) criteria based on unstructured or semistructured behavioral observations of the patients and interviews with the patients and their parents or caregivers. During the interview, the Pervasive Developmental Disorders Autism Society Japan Rating Scale (PARS) [33] and the Japanese version of the Asperger’s Questionnaire [34] were used to assist in the evaluation of ASD-specific behaviors and symptoms. PARS is a semistructured interview that is composed of

**Table 1** Demographic information for the ASD and control cohorts

| Demographics | ASD (n = 35) | Controls (n = 35) | P value |
|--------------|-------------|------------------|--------|
| Sex, M/F     | 27/8        | 26/9             |        |
| Mean age, years (± SD) | 12.9 (12.4) | 34.8 (9.7) | U = 86, P = 0.060 × 10^-5, Z = -6.19 |
| Age range, years | 3 to 63    | 21 to 65         |        |
| Number of ASD (with IQ < 70) | 35 (11) | 0                |        |
| Number of Autism (with IQ < 70) | 20 (10) | -                |        |
| Number of Asperger’s syndrome (with IQ < 70) | 11 (0) | -                |        |
| Number with PDD-NOS (with IQ < 70) | 4 (1) | -                |        |

ASD: autism spectrum disorder, M: male, F: female, IQ: intelligence quotient; PDD-NOS: pervasive developmental disorder not otherwise specified. Data are means ± SD unless otherwise specified. Differences in clinical characteristics were analyzed using the χ² test for gender and the Mann-Whitney U test for age.
57 questions in eight domains of the characteristics of children with PDD, which was developed by the Autism Society Japan. The clinicians who diagnosed the individuals were trained in the use of PARS. Twenty individuals met the full criteria for autistic disorder, 11 met the criteria for Asperger syndrome and four for PDD—not otherwise specified (PDD-NOS). Among the patients with ASD, 11 had a low intelligence quotient (IQ) (< 70). The schizophrenia cohort consisted of 45 patients with schizophrenia and 45 age- and sex-matched healthy controls (Table 2). Each patient with schizophrenia received a consensus diagnosis by at least two trained psychiatrists according to the DSM-IV-TR criteria using the structured clinical interview (SCID) for DSM-IV.

A detailed description of healthy controls was given in previous reports [35,36]. Briefly, controls were biologically unrelated Japanese participants. Healthy controls were screened using the SCID for the Diagnostic and Statistical Manual, Fourth Edition, Axis I Disorders, Non-Patient version (SCID-I/NP) and were excluded if they (1) had neurological or medical conditions that could potentially affect the central nervous system, (2) had any psychiatric diseases and/or received psychiatric medication, (3) had first- or second-degree relatives with psychiatric disease or (4) presented with an IQ < 70. IQ data were collected using the Japanese version of the full-scale Wechsler Adult Intelligence Scale (WAIS)-III or the full-scale Wechsler Intelligence Scale for Children-Third Edition (WISC-III) [37,38].

Following description of the study, written informed consent was obtained from each individual (or, when appropriate, his/her guardians). This study was carried out in accordance with the World Medical Association’s Declaration of Helsinki and was approved by the ethics committee at Osaka University.

**Immortalization of lymphocytes and RNA extraction**

Isolation of lymphocytes from blood and lymphocyte immortalization using Epstein-Barr virus (EBV) were entrusted to SRL of Tokyo, Japan. Immortalized, patient-derived lymphocytes were grown in culture media supplemented with 20% fetal bovine serum. Total RNA was extracted from cell pellets using the RNeasy Mini Kit (Qiagen K.K., Tokyo, Japan). The total RNA yield was determined by absorbance at 260 nm, and RNA quality was analyzed using agarose gel electrophoresis.

**DNase treatment and reverse transcriptase reaction**

Total RNA was treated with DNase to remove contaminating genomic DNA using DNase Treatment & Removal Reagents (Ambion, Austin, TX, USA) according to the manufacturer’s protocol. Total RNA (10 μg) treated with DNase was used in a 50-μL reverse transcriptase reaction to synthesize cDNA with the SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol. Briefly, total RNA (10 μg) was denatured with 1 mM dextroribonucleotide triphosphate (dNTP) and 5 ng/μL random hexamers at 65°C for 5 minutes. After the addition of 10xRT buffer (20 mM Tris-HCl (pH 8.4) and 50 mM KCl final concentration; Invitrogen), MgCl₂ (5 mM final concentration), dithiothreitol (10 mM final concentration), RNaseOUT Recombinant Ribonuclease Inhibitor (100 U; Invitrogen) and SuperScript III Reverse Transcriptase (125 U; Invitrogen), the reaction mixture was incubated at 25°C for 10 minutes, at 42°C for 40 minutes and at 70°C for 15 minutes. RNase H (5 U) was added to the reaction mixture and incubated at 37°C for 20 minutes to stop the reaction.

**Real-time quantitative RT-PCR**

The Pre-Developed TaqMan Assay Reagent kit (Applied Biosystems, Foster City, CA, USA) was used to measure mRNA expression levels of *NLGN3*, *NLGN4*, *NRXN1*, *SHANK3*, *MeCP2*, *NHE9*, *AKT1* and housekeeping genes (*β-actin* and *TBP*). Primers were purchased from Applied Biosystems (gene name: assay ID, transcript ID, target region; *NLGN3*: Hs01043809_m1, NM_181303.1, Exon4-5; *NLGN4*: Hs00535592_m1, NM_020742.2, Exon1-2; *NRXN1*: Hs00985123_m1, NM_001135659.1, Exon22-23; *SHANK3*: Hs01586468_m1, NM_001080420.1, Exon22-23; *MECP2*: Hs00172845_m1, NM_004992.3, Exon2-3; *NHE9*: Hs00543518_m1, NM_173653.3, Exon7-8; *AKT1*: Hs00920503_m1, NM_001014432.1, Exon13-14; *β-actin*: 4326315E, NM_001101, no region indicated; *TBP*: 4326322E, NM_001101, no region indicated). Expression levels of these genes were measured by real-time quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) using an ABI Prism 7900 Sequence Detection System (Applied Biosystems) with a 384-well format as previously described [39,40]. Each 20-μL PCR reaction contained 6 μL of cDNA, 900 nM concentrations of each primer, a 250 nM concentration of probe and 10 μL of
TaqMan Universal PCR Master Mix containing AmpliTaq Gold DNA Polymerase and AmpErase Uracil N-glycosylase (all from Applied Biosystems), as well as dNTP with deoxyuridine triphosphate, passive reference and optimized buffer components. The PCR cycling conditions were 50°C for 2 minutes, 95°C for 10 minutes, 40 cycles of 95°C for 15 seconds and 59°C or 60°C for 1 minute. PCR data were obtained by using Sequence Detector software (SDS version 2.1; Applied Biosystems) and quantified using a standard curve method. This software plotted the real-time fluorescence intensity and selected the threshold within the linear phase of the amplicon profile. The software plotted a standard curve of the cycle at threshold (Ct) (where the fluorescence generated within a reaction crossed the threshold) versus the quantity of RNA. All samples were measured using a single plate per target gene, and their Ct values were in the linear range of the standard curve. Sample quantities were predicted by Ct values. Experiments were typically performed three times in triplicate, and each gene expression level was taken as the average of three independent experiments. The individual expression level of each target gene normalized by a housekeeping gene (raw target gene expression level divided by raw housekeeping gene expression level) was used for statistical analysis.

Statistical analyses
Statistical analyses were carried out using SPSS for Windows version 16.0 software (SPSS Japan Inc., Tokyo, Japan). Group comparisons of demographic data were performed using the c2 test for one categorical variable (sex) or the Mann-Whitney U test for continuous variables as appropriate. Differences in mRNA transcript levels between the groups were analyzed using the Mann-Whitney U test. The Bonferroni correction for multiple tests was applied to assess the mRNA transcript levels on the number of genes (five). All P values reported are based on two-tailed tests. Statistical significance was defined as P < 0.05.

Results
Standard curves for the seven target genes (NLGN3, NLGN4, NRXN1, SHANK3, MeCP2, NHE9 and AKT1) and the two housekeeping genes (β-actin and TBP) were prepared using serial dilutions (1:4) of pooled cDNA from 300 ng of total RNA derived from immortalized lymphoblasts (Figure 1). The R2 values of the standard curves were more than 0.99 (NLGN3, MeCP2, NHE9, AKT1, β-actin and TBP), 0.87 (SHANK3), 0.64 (NRXN1) and 0.63 (NLGN4). Although the SHANK3 gene expression was relatively low, it was measurable in our sample. On the other hand, we did not further analyze NLGN4 and NRXN1 gene expression, as the expression levels of the two genes were too low to quantify using this method.

Using immortalized lymphoblastoid cells from 35 individuals with ASD and 35 controls, we quantified the mRNA expression levels of the NLGN3, SHANK3, NHE9, MeCP2 and AKT1 genes normalized by two housekeeping genes, β-actin and TBP (Figure 2). The mRNA expression levels of the NLGN3 gene normalized by β-actin or TBP were decreased by 35% or 26%, respectively, in individuals with ASD (β-actin: P =
mRNA expression levels of the SHANK3 gene normalized by β-actin or TBP were also decreased in individuals with ASD by 39% or 40%, respectively (β-actin: \( P = 0.00036 \); TBP: \( P = 0.0061 \)). The mRNA expression levels of the NHE9 gene were increased by 24% (\( P = 0.052 \): normalized by β-actin) and 39% (\( P = 0.048 \): normalized by TBP). There was no significant difference in mRNA expression levels of the MeCP2 gene normalized by β-actin or TBP between the two groups (\( P > 0.1 \)). The mRNA expression levels of the AKT1 gene were decreased by 11% (\( P = 0.03 \): normalized by β-actin); however, those levels were not altered when normalized by TBP (\( P = 0.45 \)). After correction for multiple tests, mRNA expression levels of NLGN3 and SHANK3 remained significantly lower in individuals with ASD than in healthy controls (NLGN3: corrected \( P = 0.0012 \), normalized by β-actin, corrected \( P = 0.0045 \), normalized by TBP; SHANK3: corrected \( P = 0.00018 \), normalized by β-actin, corrected \( P = 0.03 \), normalized by TBP). However, the altered expression level of NHE9 or AKT1 was no longer significant after the correction for multiple tests (\( P > 0.1 \)).

We next measured NLGN3 and SHANK3 mRNA expression levels in immortalized lymphoblastoid cells from 45 patients with schizophrenia and 45 healthy controls to examine the disease specificity of the differential expression levels between patients and healthy controls (Figure 3). We found that the mRNA expression levels for these two genes normalized by β-actin or TBP were not significantly different between patients with schizophrenia and healthy controls (\( P > 0.2 \)). These results suggest that reduced levels of NLGN3 and SHANK3 mRNA expression might be associated with ASD but not with schizophrenia.

**Discussion**

In this study, we found that the mRNA expression levels of NLGN3 and SHANK3 were significantly lower in individuals with ASD than in healthy controls. Mutations of causal genes are rare, and they have been found to be associated with specific types of ASD. Our findings suggest that not only rare mutations of the causal genes but also functional alterations in the transcriptional activity of these genes might be associated with the pathophysiology of ASD. The NLGN3 and SHANK3 genes are synapse-related genes and were found to be affected in ASD, whereas other genes, including NHE9 and MeCP2, do not play major roles at the synapse and were not found to be affected in ASD. These findings suggest that impairments in synaptic function might be associated with the pathophysiology of ASD.

Reduced expression of the NLGN3 and SHANK3 genes in lymphoblasts of individuals with ASD is consistent with previous reports indicating that mutations of these genes cause reduced expression or loss of function of the protein. Since the NLGN3 gene is located in chromosome X, there may be expression difference between genders. However, no significant difference of NLGN3 gene expression normalized by β-actin or TBP was observed with regard to gender in healthy controls or individuals with ASD (\( P > 0.05 \)). This might be due to inactivation of one X chromosome in females [41]. There are several possibilities that might explain the reduced expression of the NLGN3 and SHANK3 genes in ASD. First, our sporadic ASD cases might have mutations, polymorphisms or copy number variations in the NLGN3 or SHANK3 genes, which could result in reduced expression of these genes. Second, mutations or polymorphisms in genes that regulate the expression of NLGN3 or SHANK3 might contribute to the observed reduction in expression of the NLGN3 or SHANK3 genes. To our knowledge, although the regulation of NLGN3 by other genes has not been reported, there are some reports in the literature describing the regulation of SHANK3 gene expression. For example, SHANK3 expression is regulated by DNA methylation [42,43]. In addition, SHANK3 is one of the predicted targets of dysregulated microRNA (miRNA), and altered miRNA expression levels were found in postmortem brain from autism patients [44]. Further epigenetic analyses might elucidate the mechanisms of reduced SHANK3 expression.

Some findings of gene expression in lymphoblastoid cell lines are in conflict with those of previous studies. For example, Beri et al. [42] reported that SHANK3 is not expressed in EBV-transformed human lymphoblastoid cell lines in an investigation of tissue-specific

---

**Figure 3** Expression analysis of the NLGN3 and SHANK3 genes in patients with schizophrenia. Mean relative mRNA expression level scores normalized by housekeeping gene β-actin (a) or TBP (b) in the schizophrenia group and the control group are shown. Bars represent standard error of the mean. Differences in expression levels of the two genes between the groups were analyzed by using the Mann-Whitney U test.
SHANK3 gene expression and DNA methylation. By using lymphoblastoid cells from autism patients, Talebzadeh et al. [8] detected novel splice isoforms of NLGN4. There are methodological differences between previous studies and our study. SHANK3 gene expression in the previous study [42] was analyzed by using a conventional RT-PCR method; however, we measured the expression levels of SHANK3 gene by using a real-time qRT-PCR method (the TaqMan method). Furthermore, the expression level of SHANK3 was relatively low, which is shown in the standard curve in Figure 1. It is possible that the sensitivity of our real-time qRT-PCR method to detect the SHANK3 gene expression level might be higher than that of a conventional RT-PCR method. On the other hand, we could not quantitatively measure the NLGN4 and NRXN1 genes by using the real-time qRT-PCR method. However, there were slight expressions of these genes in lymphoblastoid cell lines when we used a large quantity of cDNA for the real-time qRT-PCR (Figure 1). Unfortunately, the small expression levels of these genes made it impossible to quantitatively measure the gene expressions in our sample. This may explain possible discrepancies of the gene expression findings of previous studies and our results.

There are several limitations of this study. First, our positive results might have arisen from sample bias due to non-age-matched samples, although the Japanese are a relatively homogeneous population, so the use of non-age-matched samples is unlikely to explain our findings. Second, our sample size might not be small for type I errors but small for type II errors. There is a possibility of type II errors in mRNA expression differences of NHE9, MECP2 and AKT1 between individuals with ASD and healthy controls and expression differences of NLGN3 and SHANK3 between individuals with schizophrenia and healthy controls. In particular, NHE9 might be increased in individuals with ASD, as the expression level of NHE9 was marginally significant before correction for multiple testing. Thus, replication studies using a larger sample size are needed before a firm conclusion can be drawn. Third, we did not perform a mutation search for the examined genes in our sample to replicate the association between the examined genes and ASD and how the causal or risk variants of the genes regulate the gene expression. As the previous evidence for candidate genes of ASD are based on rare mutations and/or copy number variations of the genes, it might be difficult to find a mutation in our 35 individuals with ASD for analysis of the variant effects on the gene expression in this study. A mutation search study of these candidate genes should be done in future studies. Fourth, the IQ scores in the ASD group were lower than those in the healthy control group, so reduced gene expression could be related to lower IQ. However, lower expression of the NLGN3 or SHANK3 genes was not found in individuals with schizophrenia who had lower premorbid IQ scores, and no expression difference was observed in individuals with ASD and mental retardation versus individuals with ASD but without mental retardation (data not shown). Taken together, the reduced gene expression in ASD might be specific to ASD, although other neuropsychiatric diseases, such as attention-deficit/hyperactivity disorder, mental retardation, major depression and bipolar disorder, should be examined in future studies. The ASD cases in this study were consistent with idiopathic autism diagnosed on the basis of clinical features. We did not include individuals with Rett syndrome and the other syndromic autisms, such as multiple sclerosis, which could explain why we did not find altered expression of MeCP2 in this cohort. Our results suggest that the MeCP2 gene may not be associated with the common pathology of ASD, while NLGN3 and SHANK3 may be. Because lymphoblastoid cell lines are not neuronal cells, some of our findings might not reflect the pathophysiology in ASD brains. Further studies investigating these limitations are warranted.

Conclusions

Our study reveals reduced levels of NLGN3 and SHANK3 mRNA expression in lymphoblastoid cell lines derived from individuals with ASD, but not from those of individuals with schizophrenia. These results are consistent with findings that rare mutations of these genes in specific cases cause loss of function, suggesting that reduction of NLGN3 and SHANK3 mRNA expression could be related to the pathophysiology of ASD in a substantial population of patients. Although there are several limitations present in this study, lymphoblastoid cell lines may still allow investigation of the pathophysiology of ASD. Further analyses are required, such as a mutation analysis of the NLGN3 and SHANK3 genes and the genes regulating their expression, in addition to studies designed to elucidate the mechanisms of this reduced expression.

Abbreviations

ASD, autism spectrum disorder; DSM-IV-TR, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision; F, female; IQ, intelligence quotient; JART50, Japanese Adult Reading Test; M, male; MeCP2, methyl-CpG-binding protein 2; NHE9, sodium/hydrogen exchanger 9; NLGN, neurexin; NRXN, neurexin; PARS, Pervasive Developmental Disorders Autism Society Japan Rating Scale; PDD, pervasive developmental disorder; PDD-NOS, pervasive developmental disorder not otherwise specified; SCID, structured clinical interview; SCID-HNP, Diagnostic and Statistical Manual, Fourth Edition, Axis I Disorders, Non-Patient version; SD, standard deviation; WAIS-III, Wechsler Adult Intelligence Scale-III; WISC-III, Wechsler Intelligence Scale for Children-Third Edition.

Acknowledgements

This work was funded in part by Grants-in-Aid from the Japanese Ministry of Health, Labor and Welfare (H19-kokoro-002, H22-seishin-ippan-001, H22-
Yasuda et al. Molecular Autism 2011, 2:9

http://www.molecularautism.com/content/2/1/9

Page 7 of 8

References

1. Levy SE, Mandell DS, Schultz RT. Autism. Lancet 2009, 374:1627-1638.

2. Lichtenstein P, Carlström E, Råstam M, Gillberg C, Anckarsäter H. The genetics of autism spectrum disorders and related neuropsychiatric disorders in childhood. Am J Psychiatry 2010, 167:1357-1363.

3. Walsh CA, Morrow EM, Rubenstein JL. Autism and brain development. Cell 2008, 133:396-400.

4. Jamain S, Quach H, Betancur C, Rastam M, Gillberg C, Andersson H. The genes of autism spectrum disorders and related neuropsychiatric disorders associated with autism. Nat Genet 2003, 34:27-29.

5. Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moizard MP, Laumonnier F, Bonnet-Brilhault F, Gomot M, Blanc R, David A, Moiz...
compromised in the brain of autistic subjects. J Neurosci Res 88:2641-2647.

26. Zhou J, Blundell J, Ogawa S, Kwon CH, Zhang W, Sinton C, Powell CM, Parada LF: Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice. J Neurosci 2009, 29:1773-1783.

27. Honke S, Cai S, Miyano M, Cheng JF, Kohwi-Shigematsu T: Loss of silent-chromatin looping and impaired imprinting of DLK5 in Rett syndrome. Nat Genet 2005, 37:31-40.

28. Meloni I, Muscettola M, Raynaud M, Longo I, Brutini M, Moizard MP, Gomot M, Chelly J, des Portes V, Frays FJ, Ropers HH, Marji B, Bellan C, Volpi N, Yntema HG, Lewis SE, Schaffer JE, Renen A: FACL4, encoding fatty acid-CoA ligase 4, is mutated in nonspecific X-linked mental retardation. Nat Genet 2002, 30:436-440.

29. Iwamoto K, Kakiuchi C, Bundo M, Ikeda K, Kato T: Molecular characterization of bipolar disorder by comparing gene expression profiles of postmortem brains of major mental disorders. Mol Psychiatry 2004, 9:406-416.

30. Brown V, Jin P, Ceman S, Darnell JC, Oakes WA: Identification of FGFR2B-associated brain mRNAs and altered mRNA transcriptional profiles in fragile X syndrome. Cell 2001, 107:477-487.

31. Nishimura Y, Martin CL, Vazquez-Lopez A, Spence SJ, Akazawa-Redueto A, Sigman M, Stendler P, Pellegini S, Schen N, Warren ST, Geschwind DH: Genome-wide expression profiling of lymphoblastoid cell lines distinguishes different forms of autism and reveals shared pathways. Hum Mol Genet 2007, 16:1682-1698.

32. Baron CA, Tepper CG, Liu SY, Davis RR, Wang NJ, Schanen NC, Gregg JP: Genomic and functional profiling of duplicated chromosome 15 cell lines reveal regulatory alterations in UBE3A-associated ubiquitin-proteasome pathway processes. Hum Mol Genet 2006, 15:853-869.

33. Yamada A, Suzuki M, Kato M, Tanaka S, Shindo T, Taketani K, Akechi T, Furukawa TA: Emotional distress and its correlates among parents of children with pervasive developmental disorders. Psychiatry Clin Neurosci 2007, 61:651-657.

34. Wakabayashi A, Tojo Y, Baron-Cohen S, Wheelwright S: [The Autism-Spectrum Quotient (AQ) Japanese version: evidence from high-functioning clinical group and normal adults] [in Japanese]. Shinrigaku Kenkyu 2004, 75:78-84.

35. Yasuda Y, Hashimoto R, Oki H, Fukumoto M, Yakumura H, Iike N, Yoshihara T, Hayashi N, Takahashi H, Yamamoto H, Morihara T, Tagami S, Okochi M, Tanaka T, Kudo T, Kamino K, Ishi R, Iwase M, Kazui H, Takeda M: Association study of XIIIB gene with memory performance in a Japanese population. World J Biol Psychiatry 2010, 11:852-857.

36. Hashimoto R, Oki H, Yasuda Y, Fukumoto M, Iwase M, Iike N, Azuchi M, Ikekawa K, Takayama M, Takahashi H, Yamamoto H, Okochi T, Tanikuma H, Tagami S, Morihara T, Okochi M, Tanaka T, Kudo T, Kazui H, Iwata N, Takeda M: The impact of a genome-wide supported psychosis variant in the ZNF804A gene on memory function in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2010, 153B:1459-1464.

37. Committee JWP: Japanese Wechsler Intelligence Scale for Children Tokyo: Nihon Bunka Kagakusha, 1998.

38. Wechsler D: Wechsler Intelligence Scale for Children-Third Edition Manual New York: Psychological Corp, 1991.

39. Hashimoto R, Straub RE, Weickert CS, Hyde TM, Kleinman JE, Weinberger DR: Expression analysis of neuregulin-1 in the dorsolateral prefrontal cortex in schizophrenia. Mol Psychiatry 2004, 9:299-307.

40. Chiba S, Hashimoto R, Hatton S, Yokoda M, Lipka B, Weinberger DR, Kurug H: Effect of antipsychotic drugs on DSC1 and dysbindin expression in mouse frontal cortex and hippocampus. J Neural Transm 2006, 113:1337-1346.

41. Willard HF: X chromosome inactivation and X-linked mental retardation. Am J Med Genet 1996, 64:21-26.

42. Ben S, Tonina N, Menozzi G, Bonaglia MC, Sala C, Giorda R: DNA methylation regulates tissue-specific expression of Shank3. J Neurochem 2007, 101:1380-1391.

43. Maunakea AK, Nagarajan RP, Bilenky M, Ballinger TJ, O’Souza C, Fouse SD, Johnson BE, Hong C, Nielsen C, Zhao Y, Turecki G, Delaney A, Varhol R, Thiessen N, Shihors K, Heine VM, Rowitch DH, Xing X, Fiore C, Schollebeck M, Jones SJ, Haussler D, Marra MA, Hirst M, Wang T, Costello JF: Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 2010, 466:253-257.

44. Abu-Elneel K, Liu T, Gazzaniga FS, Nishimura Y, Wall DP, Geschwind DH, Lao K, Kosik KS: Heterogeneous dysregulation of microRNAs across the autism spectrum. Neurogenetics 2008, 9:153-161.